Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis

被引:0
作者
Rachel Harrington
Edward Lee
Hongbo Yang
Jin Wei
Andrew Messali
Nkechi Azie
Eric Q. Wu
James Spalding
机构
[1] Astellas Pharma Global Development,
[2] Analysis Group,undefined
[3] Inc.,undefined
来源
Advances in Therapy | 2017年 / 34卷
关键词
Cost-effectiveness; Invasive aspergillosis; Infectious diseases; Isavuconazole; Phase III trial; Sensitivity analyses; Voriconazole;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:207 / 220
页数:13
相关论文
共 97 条
[1]  
Kousha M(2011)Pulmonary aspergillosis: a clinical review Eur Respir Rev 20 156-174
[2]  
Tadi R(2001)Aspergillosis case-fatality rate: systematic review of the literature Clin Infect Dis 32 358-366
[3]  
Soubani AO(2010)The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients Int J Antimicrob Agents 36 531-536
[4]  
Lin SJ(2002)Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis 34 909-917
[5]  
Schranz J(2007)Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality Clin Infect Dis 44 531-540
[6]  
Teutsch SM(2011)Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States Mycoses 54 e301-e312
[7]  
Perkhofer S(2009)The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups Int J Infect Dis 13 24-36
[8]  
Lass-Florl C(2008)Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 327-360
[9]  
Hell M(1998)Invasive Aspergillosis Clin Infect Dis 26 781-803
[10]  
Marr KA(2009)Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies Clinicoecon Outcomes Res 1 35-43